Illumina Inc
ILMNIllumina Inc (ILMN) is a biotechnology company specializing in genomic-focused solutions, including sequencing and array-based technologies. Founded in 1998, Illumina provides tools and services for genetic research, clinical applications, and molecular diagnostics, playing a key role in advancing personalized medicine and genomic science.
Company News
The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment...
ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions ...
The global environmental DNA (eDNA) market is expected to grow at a CAGR of 10.2% from 2026 to 2031, driven by non-invasive species detection methods, stricter environmental regulations, and increasing demand for ecosystem health monitoring. North America leads the market with advanced research infrastructure and strong public-private collaborati...
The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and...
The global spatial genomics and transcriptomics market is projected to grow from USD 0.60 billion in 2025 to USD 1.90 billion by 2035 at a 12.23% CAGR. Growth is driven by increased adoption of AI-powered spatial biology technologies, precision medicine initiatives, and high-resolution molecular profiling in oncology and translational research. N...
